Table of Content

1 Hepatic Encephalopathy Drugs Market Overview
1.1 Hepatic Encephalopathy Drugs Product Scope
1.2 Hepatic Encephalopathy Drugs Segment by Type
1.2.1 Global Hepatic Encephalopathy Drugs Sales by Type (2016 & 2021 & 2027)
1.2.2 Injection
1.2.3 Oral
1.3 Hepatic Encephalopathy Drugs Segment by Application
1.3.1 Global Hepatic Encephalopathy Drugs Sales Comparison by Application (2016 & 2021 & 2027)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Hepatic Encephalopathy Drugs Market Estimates and Forecasts (2016-2027)
1.4.1 Global Hepatic Encephalopathy Drugs Market Size in Value Growth Rate (2016-2027)
1.4.2 Global Hepatic Encephalopathy Drugs Market Size in Volume Growth Rate (2016-2027)
1.4.3 Global Hepatic Encephalopathy Drugs Price Trends (2016-2027)

2 Hepatic Encephalopathy Drugs Estimates and Forecasts by Region
2.1 Global Hepatic Encephalopathy Drugs Market Size by Region: 2016 VS 2021 VS 2027
2.2 Global Hepatic Encephalopathy Drugs Retrospective Market Scenario by Region (2016-2021)
2.2.1 Global Hepatic Encephalopathy Drugs Sales Market Share by Region (2016-2021)
2.2.2 Global Hepatic Encephalopathy Drugs Revenue Market Share by Region (2016-2021)
2.3 Global Hepatic Encephalopathy Drugs Market Estimates and Forecasts by Region (2022-2027)
2.3.1 Global Hepatic Encephalopathy Drugs Sales Estimates and Forecasts by Region (2022-2027)
2.3.2 Global Hepatic Encephalopathy Drugs Revenue Forecast by Region (2022-2027)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 North America Hepatic Encephalopathy Drugs Estimates and Projections (2016-2027)
2.4.2 Europe Hepatic Encephalopathy Drugs Estimates and Projections (2016-2027)
2.4.3 China Hepatic Encephalopathy Drugs Estimates and Projections (2016-2027)
2.4.4 Japan Hepatic Encephalopathy Drugs Estimates and Projections (2016-2027)
2.4.5 Southeast Asia Hepatic Encephalopathy Drugs Estimates and Projections (2016-2027)
2.4.6 India Hepatic Encephalopathy Drugs Estimates and Projections (2016-2027)
3 Global Hepatic Encephalopathy Drugs Competition Landscape by Players
3.1 Global Top Hepatic Encephalopathy Drugs Players by Sales (2016-2021)
3.2 Global Top Hepatic Encephalopathy Drugs Players by Revenue (2016-2021)
3.3 Global Hepatic Encephalopathy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Hepatic Encephalopathy Drugs as of 2020)
3.4 Global Hepatic Encephalopathy Drugs Average Price by Company (2016-2021)
3.5 Manufacturers Hepatic Encephalopathy Drugs Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Global Hepatic Encephalopathy Drugs Market Size by Type
4.1 Global Hepatic Encephalopathy Drugs Historic Market Review by Type (2016-2021)
4.1.1 Global Hepatic Encephalopathy Drugs Sales Market Share by Type (2016-2021)
4.1.2 Global Hepatic Encephalopathy Drugs Revenue Market Share by Type (2016-2021)
4.1.3 Global Hepatic Encephalopathy Drugs Price by Type (2016-2021)
4.2 Global Hepatic Encephalopathy Drugs Market Estimates and Forecasts by Type (2022-2027)
4.2.1 Global Hepatic Encephalopathy Drugs Sales Forecast by Type (2022-2027)
4.2.2 Global Hepatic Encephalopathy Drugs Revenue Forecast by Type (2022-2027)
4.2.3 Global Hepatic Encephalopathy Drugs Price Forecast by Type (2022-2027)
5 Global Hepatic Encephalopathy Drugs Market Size by Application
5.1 Global Hepatic Encephalopathy Drugs Historic Market Review by Application (2016-2021)
5.1.1 Global Hepatic Encephalopathy Drugs Sales Market Share by Application (2016-2021)
5.1.2 Global Hepatic Encephalopathy Drugs Revenue Market Share by Application (2016-2021)
5.1.3 Global Hepatic Encephalopathy Drugs Price by Application (2016-2021)
5.2 Global Hepatic Encephalopathy Drugs Market Estimates and Forecasts by Application (2022-2027)
5.2.1 Global Hepatic Encephalopathy Drugs Sales Forecast by Application (2022-2027)
5.2.2 Global Hepatic Encephalopathy Drugs Revenue Forecast by Application (2022-2027)
5.2.3 Global Hepatic Encephalopathy Drugs Price Forecast by Application (2022-2027)

6 North America Hepatic Encephalopathy Drugs Market Facts & Figures
6.1 North America Hepatic Encephalopathy Drugs Sales by Company
6.1.1 North America Hepatic Encephalopathy Drugs Sales by Company (2016-2021)
6.1.2 North America Hepatic Encephalopathy Drugs Revenue by Company (2016-2021)
6.2 North America Hepatic Encephalopathy Drugs Sales Breakdown by Type
6.2.1 North America Hepatic Encephalopathy Drugs Sales Breakdown by Type (2016-2021)
6.2.2 North America Hepatic Encephalopathy Drugs Sales Breakdown by Type (2022-2027)
6.3 North America Hepatic Encephalopathy Drugs Sales Breakdown by Application
6.3.1 North America Hepatic Encephalopathy Drugs Sales Breakdown by Application (2016-2021)
6.3.2 North America Hepatic Encephalopathy Drugs Sales Breakdown by Application (2022-2027)

7 Europe Hepatic Encephalopathy Drugs Market Facts & Figures
7.1 Europe Hepatic Encephalopathy Drugs Sales by Company
7.1.1 Europe Hepatic Encephalopathy Drugs Sales by Company (2016-2021)
7.1.2 Europe Hepatic Encephalopathy Drugs Revenue by Company (2016-2021)
7.2 Europe Hepatic Encephalopathy Drugs Sales Breakdown by Type
7.2.1 Europe Hepatic Encephalopathy Drugs Sales Breakdown by Type (2016-2021)
7.2.2 Europe Hepatic Encephalopathy Drugs Sales Breakdown by Type (2022-2027)
7.3 Europe Hepatic Encephalopathy Drugs Sales Breakdown by Application
7.3.1 Europe 130 Sales Breakdown by Application (2016-2021)
7.3.2 Europe 130 Sales Breakdown by Application (2022-2027)

8 China Hepatic Encephalopathy Drugs Market Facts & Figures
8.1 China Hepatic Encephalopathy Drugs Sales by Company
8.1.1 China Hepatic Encephalopathy Drugs Sales by Company (2016-2021)
8.1.2 China Hepatic Encephalopathy Drugs Revenue by Company (2016-2021)
8.2 China Hepatic Encephalopathy Drugs Sales Breakdown by Type
8.2.1 China Hepatic Encephalopathy Drugs Sales Breakdown by Type (2016-2021)
8.2.2 China Hepatic Encephalopathy Drugs Sales Breakdown by Type (2022-2027)
8.3 China Hepatic Encephalopathy Drugs Sales Breakdown by Application
8.3.1 China 241 Sales Breakdown by Application (2016-2021)
8.3.2 China 241 Sales Breakdown by Application (2022-2027)

9 Japan Hepatic Encephalopathy Drugs Market Facts & Figures
9.1 Japan Hepatic Encephalopathy Drugs Sales by Company
9.1.1 Japan Hepatic Encephalopathy Drugs Sales by Company (2016-2021)
9.1.2 Japan Hepatic Encephalopathy Drugs Revenue by Company (2016-2021)
9.2 Japan Hepatic Encephalopathy Drugs Sales Breakdown by Type
9.2.1 Japan Hepatic Encephalopathy Drugs Sales Breakdown by Type (2016-2021)
9.2.2 Japan Hepatic Encephalopathy Drugs Sales Breakdown by Type (2022-2027)
9.3 Japan Hepatic Encephalopathy Drugs Sales Breakdown by Application
9.3.1 Japan Feb. Sales Breakdown by Application (2016-2021)
9.3.2 Japan Feb. Sales Breakdown by Application (2022-2027)

10 Southeast Asia Hepatic Encephalopathy Drugs Market Facts & Figures
10.1 Southeast Asia Hepatic Encephalopathy Drugs Sales by Company
10.1.1 Southeast Asia Hepatic Encephalopathy Drugs Sales by Company (2016-2021)
10.1.2 Southeast Asia Hepatic Encephalopathy Drugs Revenue by Company (2016-2021)
10.2 Southeast Asia Hepatic Encephalopathy Drugs Sales Breakdown by Type
10.2.1 Southeast Asia Hepatic Encephalopathy Drugs Sales Breakdown by Type (2016-2021)
10.2.2 Southeast Asia Hepatic Encephalopathy Drugs Sales Breakdown by Type (2022-2027)
10.3 Southeast Asia Hepatic Encephalopathy Drugs Sales Breakdown by Application
10.3.1 Southeast Asia MT Sales Breakdown by Application (2016-2021)
10.3.2 Southeast Asia MT Sales Breakdown by Application (2022-2027)

11 India Hepatic Encephalopathy Drugs Market Facts & Figures
11.1 India Hepatic Encephalopathy Drugs Sales by Company
11.1.1 India Hepatic Encephalopathy Drugs Sales by Company (2016-2021)
11.1.2 India Hepatic Encephalopathy Drugs Revenue by Company (2016-2021)
11.2 India Hepatic Encephalopathy Drugs Sales Breakdown by Type
11.2.1 India Hepatic Encephalopathy Drugs Sales Breakdown by Type (2016-2021)
11.2.2 India Hepatic Encephalopathy Drugs Sales Breakdown by Type (2022-2027)
11.3 India Hepatic Encephalopathy Drugs Sales Breakdown by Application
11.3.1 India Hepatic Encephalopathy Drugs Sales Breakdown by Application (2016-2021)
11.3.2 India Hepatic Encephalopathy Drugs Sales Breakdown by Application (2022-2027)

12 Company Profiles and Key Figures in Hepatic Encephalopathy Drugs Business
12.1 ASKA Pharmaceutical
12.1.1 ASKA Pharmaceutical Corporation Information
12.1.2 ASKA Pharmaceutical Business Overview
12.1.3 ASKA Pharmaceutical Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2016-2021)
12.1.4 ASKA Pharmaceutical Hepatic Encephalopathy Drugs Products Offered
12.1.5 ASKA Pharmaceutical Recent Development
12.2 Cosmo Pharmaceuticals
12.2.1 Cosmo Pharmaceuticals Corporation Information
12.2.2 Cosmo Pharmaceuticals Business Overview
12.2.3 Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2016-2021)
12.2.4 Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Products Offered
12.2.5 Cosmo Pharmaceuticals Recent Development
12.3 Bausch Health
12.3.1 Bausch Health Corporation Information
12.3.2 Bausch Health Business Overview
12.3.3 Bausch Health Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2016-2021)
12.3.4 Bausch Health Hepatic Encephalopathy Drugs Products Offered
12.3.5 Bausch Health Recent Development
12.4 Ferring Pharmaceuticals
12.4.1 Ferring Pharmaceuticals Corporation Information
12.4.2 Ferring Pharmaceuticals Business Overview
12.4.3 Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2016-2021)
12.4.4 Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Products Offered
12.4.5 Ferring Pharmaceuticals Recent Development
12.5 Mallinckrodt
12.5.1 Mallinckrodt Corporation Information
12.5.2 Mallinckrodt Business Overview
12.5.3 Mallinckrodt Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2016-2021)
12.5.4 Mallinckrodt Hepatic Encephalopathy Drugs Products Offered
12.5.5 Mallinckrodt Recent Development
12.6 Umecrine Cognition
12.6.1 Umecrine Cognition Corporation Information
12.6.2 Umecrine Cognition Business Overview
12.6.3 Umecrine Cognition Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2016-2021)
12.6.4 Umecrine Cognition Hepatic Encephalopathy Drugs Products Offered
12.6.5 Umecrine Cognition Recent Development
12.7 Norgine
12.7.1 Norgine Corporation Information
12.7.2 Norgine Business Overview
12.7.3 Norgine Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2016-2021)
12.7.4 Norgine Hepatic Encephalopathy Drugs Products Offered
12.7.5 Norgine Recent Development
12.8 Lupin
12.8.1 Lupin Corporation Information
12.8.2 Lupin Business Overview
12.8.3 Lupin Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2016-2021)
12.8.4 Lupin Hepatic Encephalopathy Drugs Products Offered
12.8.5 Lupin Recent Development
12.9 Kaleido Biosciences
12.9.1 Kaleido Biosciences Corporation Information
12.9.2 Kaleido Biosciences Business Overview
12.9.3 Kaleido Biosciences Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2016-2021)
12.9.4 Kaleido Biosciences Hepatic Encephalopathy Drugs Products Offered
12.9.5 Kaleido Biosciences Recent Development
12.10 Kannalife Sciences
12.10.1 Kannalife Sciences Corporation Information
12.10.2 Kannalife Sciences Business Overview
12.10.3 Kannalife Sciences Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2016-2021)
12.10.4 Kannalife Sciences Hepatic Encephalopathy Drugs Products Offered
12.10.5 Kannalife Sciences Recent Development

13 Hepatic Encephalopathy Drugs Manufacturing Cost Analysis
13.1 Hepatic Encephalopathy Drugs Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Hepatic Encephalopathy Drugs
13.4 Hepatic Encephalopathy Drugs Industrial Chain Analysis

14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Hepatic Encephalopathy Drugs Distributors List
14.3 Hepatic Encephalopathy Drugs Customers

15 Market Dynamics
15.1 Hepatic Encephalopathy Drugs Market Trends
15.2 Hepatic Encephalopathy Drugs Drivers
15.3 Hepatic Encephalopathy Drugs Market Challenges
15.4 Hepatic Encephalopathy Drugs Market Restraints

16 Research Findings and Conclusion

17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Hepatic Encephalopathy Drugs Sales (US$ Million) Growth Rate by Type (2016 & 2021 & 2027)
Table 2. Global Hepatic Encephalopathy Drugs Sales ((US$ Million)) Comparison by Application (2016 & 2021 & 2027)
Table 3. Global Hepatic Encephalopathy Drugs Market Size (US$ Million) by Region: 2016 VS 2021 &2027
Table 4. Global Hepatic Encephalopathy Drugs Sales (MT) by Region (2016-2021)
Table 5. Global Hepatic Encephalopathy Drugs Sales Market Share by Region (2016-2021)
Table 6. Global Hepatic Encephalopathy Drugs Revenue (US$ Million) Market Share by Region (2016-2021))
Table 7. Global Hepatic Encephalopathy Drugs Revenue Share by Region (2016-2021)
Table 8. Global Hepatic Encephalopathy Drugs Sales (MT) Forecast by Region (2022-2027)
Table 9. Global Hepatic Encephalopathy Drugs Sales Market Share Forecast by Region (2022-2027)
Table 10. Global Hepatic Encephalopathy Drugs Revenue (US$ Million) Forecast by Region (2022-2027)
Table 11. Global Hepatic Encephalopathy Drugs Revenue Share Forecast by Region (2022-2027)
Table 12. Global Hepatic Encephalopathy Drugs Sales (MT) of Key Companies (2016-2021)
Table 13. Global Hepatic Encephalopathy Drugs Sales Share by Company (2016-2021)
Table 14. Global Hepatic Encephalopathy Drugs Revenue (US$ Million) by Company (2016-2021)
Table 15. Global Hepatic Encephalopathy Drugs Revenue Share by Company (2016-2021)
Table 16. Global Hepatic Encephalopathy Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hepatic Encephalopathy Drugs as of 2020)
Table 17. Global Hepatic Encephalopathy Drugs Average Price (USD/Kg) of Key Company (2016-2021)
Table 18. Manufacturers Hepatic Encephalopathy Drugs Manufacturing Sites and Area Served
Table 19. Manufacturers Hepatic Encephalopathy Drugs Product Type
Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 21. Global Hepatic Encephalopathy Drugs Sales (MT) by Type (2016-2021)
Table 22. Global Hepatic Encephalopathy Drugs Sales Share by Type (2016-2021)
Table 23. Global Hepatic Encephalopathy Drugs Revenue (US$ Million) Market Share by Type (2016-2021)
Table 24. Global Hepatic Encephalopathy Drugs Price (USD/Kg) by Type (2016-2021)
Table 25. Global Hepatic Encephalopathy Drugs Sales Share by Type (2022-2027)
Table 26. Global Hepatic Encephalopathy Drugs Revenue (US$ Million) Market Share by Type (2022-2027)
Table 27. Global Hepatic Encephalopathy Drugs Revenue Share by Type (2022-2027)
Table 28. Global Hepatic Encephalopathy Drugs Price (USD/Kg) by Type (2022-2027)
Table 29. Global Hepatic Encephalopathy Drugs Sales (MT) by Application (2016-2021)
Table 30. Global Hepatic Encephalopathy Drugs Sales Share by Application (2016-2021)
Table 31. Global Hepatic Encephalopathy Drugs Revenue (US$ Million) Market Share by Application (2016-2021)
Table 32. Global Hepatic Encephalopathy Drugs Price (USD/Kg) by Application (2016-2021)
Table 33. Global Hepatic Encephalopathy Drugs Sales (MT) by Application (2022-2027)
Table 34. Global Hepatic Encephalopathy Drugs Sales Share by Application (2022-2027)
Table 35. Global Hepatic Encephalopathy Drugs Revenue (US$ Million) Market Share by Application (2022-2027)
Table 36. Global Hepatic Encephalopathy Drugs Revenue Share by Application (2022-2027)
Table 37. Global Hepatic Encephalopathy Drugs Price (USD/Kg) by Application (2022-2027)
Table 38. North America Hepatic Encephalopathy Drugs Sales (MT) by Company (2016-2021)
Table 39. North America Hepatic Encephalopathy Drugs Sales Market Share by Company (2016-2021)
Table 40. North America Hepatic Encephalopathy Drugs Revenue by Company (2016-2021) & (US$ Million)
Table 41. North America Hepatic Encephalopathy Drugs Revenue Market Share by Company (2016-2021)
Table 42. North America Hepatic Encephalopathy Drugs Sales by Type (2016-2021) & (MT)
Table 43. North America Hepatic Encephalopathy Drugs Sales Market Share by Type (2016-2021)
Table 44. North America Hepatic Encephalopathy Drugs Sales by Type (2022-2027) & (MT)
Table 45. North America Hepatic Encephalopathy Drugs Sales Market Share by Type (2022-2027)
Table 46. North America Hepatic Encephalopathy Drugs Sales by Application (2016-2021) & (MT)
Table 47. North America Hepatic Encephalopathy Drugs Sales Market Share by Application (2016-2021)
Table 48. North America Hepatic Encephalopathy Drugs Sales by Application (2022-2027) & (MT)
Table 49. North America Hepatic Encephalopathy Drugs Sales Market Share by Application (2022-2027)
Table 50. Europe Hepatic Encephalopathy Drugs Sales (MT) by Company (2016-2021)
Table 51. Europe Hepatic Encephalopathy Drugs Sales Market Share by Company (2016-2021)
Table 52. Europe Hepatic Encephalopathy Drugs Revenue by Company (2016-2021) & (US$ Million)
Table 53. Europe Hepatic Encephalopathy Drugs Revenue Market Share by Company (2016-2021)
Table 54. Europe Hepatic Encephalopathy Drugs Sales by Type (2016-2021) & (MT)
Table 55. Europe Hepatic Encephalopathy Drugs Sales Market Share by Type (2016-2021)
Table 56. Europe Hepatic Encephalopathy Drugs Sales by Type (2022-2027) & (MT)
Table 57. Europe Hepatic Encephalopathy Drugs Sales Market Share by Type (2022-2027)
Table 58. Europe Hepatic Encephalopathy Drugs Sales by Application (2016-2021) & (MT)
Table 59. Europe Hepatic Encephalopathy Drugs Sales Market Share by Application (2016-2021)
Table 60. Europe Hepatic Encephalopathy Drugs Sales by Application (2022-2027) & (MT)
Table 61. Europe Hepatic Encephalopathy Drugs Sales Market Share by Application (2022-2027)
Table 62. China Hepatic Encephalopathy Drugs Sales (MT) by Company (2016-2021)
Table 63. China Hepatic Encephalopathy Drugs Sales Market Share by Company (2016-2021)
Table 64. China Hepatic Encephalopathy Drugs Revenue by Company (2016-2021) & (US$ Million)
Table 65. China Hepatic Encephalopathy Drugs Revenue Market Share by Company (2016-2021)
Table 66. China Hepatic Encephalopathy Drugs Sales by Type (2016-2021) & (MT)
Table 67. China Hepatic Encephalopathy Drugs Sales Market Share by Type (2016-2021)
Table 68. China Hepatic Encephalopathy Drugs Sales by Type (2022-2027) & (MT)
Table 69. China Hepatic Encephalopathy Drugs Sales Market Share by Type (2022-2027)
Table 70. China Hepatic Encephalopathy Drugs Sales by Application (2016-2021) & (MT)
Table 71. China Hepatic Encephalopathy Drugs Sales Market Share by Application (2016-2021)
Table 72. China Hepatic Encephalopathy Drugs Sales by Application (2022-2027) & (MT)
Table 73. China Hepatic Encephalopathy Drugs Sales Market Share by Application (2022-2027)
Table 74. Japan Hepatic Encephalopathy Drugs Sales (MT) by Company (2016-2021)
Table 75. Japan Hepatic Encephalopathy Drugs Sales Market Share by Company (2016-2021)
Table 76. Japan Hepatic Encephalopathy Drugs Revenue by Company (2016-2021) & (US$ Million)
Table 77. Japan Hepatic Encephalopathy Drugs Revenue Market Share by Company (2016-2021)
Table 78. Japan Hepatic Encephalopathy Drugs Sales by Type (2016-2021) & (MT)
Table 79. Japan Hepatic Encephalopathy Drugs Sales Market Share by Type (2016-2021)
Table 80. Japan Hepatic Encephalopathy Drugs Sales by Type (2022-2027) & (MT)
Table 81. Japan Hepatic Encephalopathy Drugs Sales Market Share by Type (2022-2027)
Table 82. Japan Hepatic Encephalopathy Drugs Sales by Application (2016-2021) & (MT)
Table 83. Japan Hepatic Encephalopathy Drugs Sales Market Share by Application (2016-2021)
Table 84. Japan Hepatic Encephalopathy Drugs Sales by Application (2022-2027) & (MT)
Table 85. Japan Hepatic Encephalopathy Drugs Sales Market Share by Application (2022-2027)
Table 86. Southeast Asia Hepatic Encephalopathy Drugs Sales (MT) by Company (2016-2021)
Table 87. Southeast Asia Hepatic Encephalopathy Drugs Sales Market Share by Company (2016-2021)
Table 88. Southeast Asia Hepatic Encephalopathy Drugs Revenue by Company (2016-2021) & (US$ Million)
Table 89. Southeast Asia Hepatic Encephalopathy Drugs Revenue Market Share by Company (2016-2021)
Table 90. Southeast Asia Hepatic Encephalopathy Drugs Sales by Type (2016-2021) & (MT)
Table 91. Southeast Asia Hepatic Encephalopathy Drugs Sales Market Share by Type (2016-2021)
Table 92. Southeast Asia Hepatic Encephalopathy Drugs Sales by Type (2022-2027) & (MT)
Table 93. Southeast Asia Hepatic Encephalopathy Drugs Sales Market Share by Type (2022-2027)
Table 94. Southeast Asia Hepatic Encephalopathy Drugs Sales by Application (2016-2021) & (MT)
Table 95. Southeast Asia Hepatic Encephalopathy Drugs Sales Market Share by Application (2016-2021)
Table 96. Southeast Asia Hepatic Encephalopathy Drugs Sales by Application (2022-2027) & (MT)
Table 97. Southeast Asia Hepatic Encephalopathy Drugs Sales Market Share by Application (2022-2027)
Table 98. India Hepatic Encephalopathy Drugs Sales (MT) by Company (2016-2021)
Table 99. India Hepatic Encephalopathy Drugs Sales Market Share by Company (2016-2021)
Table 100. India Hepatic Encephalopathy Drugs Revenue by Company (2016-2021) & (US$ Million)
Table 101. India Hepatic Encephalopathy Drugs Revenue Market Share by Company (2016-2021)
Table 102. India Hepatic Encephalopathy Drugs Sales by Type (2016-2021) & (MT)
Table 103. India Hepatic Encephalopathy Drugs Sales Market Share by Type (2016-2021)
Table 104. India Hepatic Encephalopathy Drugs Sales by Type (2022-2027) & (MT)
Table 105. India Hepatic Encephalopathy Drugs Sales Market Share by Type (2022-2027)
Table 106. India Hepatic Encephalopathy Drugs Sales by Application (2016-2021) & (MT)
Table 107. India Hepatic Encephalopathy Drugs Sales Market Share by Application (2016-2021)
Table 108. India Hepatic Encephalopathy Drugs Sales by Application (2022-2027) & (MT)
Table 109. India Hepatic Encephalopathy Drugs Sales Market Share by Application (2022-2027)
Table 110. ASKA Pharmaceutical Corporation Information
Table 111. ASKA Pharmaceutical Description and Business Overview
Table 112. ASKA Pharmaceutical Hepatic Encephalopathy Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2016-2021)
Table 113. ASKA Pharmaceutical Hepatic Encephalopathy Drugs Product
Table 114. ASKA Pharmaceutical Recent Development
Table 115. Cosmo Pharmaceuticals Corporation Information
Table 116. Cosmo Pharmaceuticals Description and Business Overview
Table 117. Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2016-2021)
Table 118. Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Product
Table 119. Cosmo Pharmaceuticals Recent Development
Table 120. Bausch Health Corporation Information
Table 121. Bausch Health Description and Business Overview
Table 122. Bausch Health Hepatic Encephalopathy Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2016-2021)
Table 123. Bausch Health Hepatic Encephalopathy Drugs Product
Table 124. Bausch Health Recent Development
Table 125. Ferring Pharmaceuticals Corporation Information
Table 126. Ferring Pharmaceuticals Description and Business Overview
Table 127. Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2016-2021)
Table 128. Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Product
Table 129. Ferring Pharmaceuticals Recent Development
Table 130. Mallinckrodt Corporation Information
Table 131. Mallinckrodt Description and Business Overview
Table 132. Mallinckrodt Hepatic Encephalopathy Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2016-2021)
Table 133. Mallinckrodt Hepatic Encephalopathy Drugs Product
Table 134. Mallinckrodt Recent Development
Table 135. Umecrine Cognition Corporation Information
Table 136. Umecrine Cognition Description and Business Overview
Table 137. Umecrine Cognition Hepatic Encephalopathy Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2016-2021)
Table 138. Umecrine Cognition Hepatic Encephalopathy Drugs Product
Table 139. Umecrine Cognition Recent Development
Table 140. Norgine Corporation Information
Table 141. Norgine Description and Business Overview
Table 142. Norgine Hepatic Encephalopathy Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2016-2021)
Table 143. Norgine Hepatic Encephalopathy Drugs Product
Table 144. Norgine Recent Development
Table 145. Lupin Corporation Information
Table 146. Lupin Hepatic Encephalopathy Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2016-2021)
Table 147. Lupin Description and Business Overview
Table 148. Lupin Hepatic Encephalopathy Drugs Product
Table 149. Lupin Recent Development
Table 150. Kaleido Biosciences Corporation Information
Table 151. Kaleido Biosciences Hepatic Encephalopathy Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2016-2021)
Table 152. Kaleido Biosciences Description and Business Overview
Table 153. Kaleido Biosciences Hepatic Encephalopathy Drugs Product
Table 154. Kaleido Biosciences Recent Development
Table 155. Kannalife Sciences Corporation Information
Table 156. Kannalife Sciences Description and Business Overview
Table 157. Kannalife Sciences Hepatic Encephalopathy Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2016-2021)
Table 158. Kannalife Sciences Hepatic Encephalopathy Drugs Product
Table 159. Kannalife Sciences Recent Development
Table 160. Production Base and Market Concentration Rate of Raw Material
Table 161. Key Suppliers of Raw Materials
Table 162. Hepatic Encephalopathy Drugs Distributors List
Table 163. Hepatic Encephalopathy Drugs Customers List
Table 164. Hepatic Encephalopathy Drugs Market Trends
Table 165. Hepatic Encephalopathy Drugs Market Drivers
Table 166. Hepatic Encephalopathy Drugs Market Challenges
Table 167. Hepatic Encephalopathy Drugs Market Restraints
Table 168. Research Programs/Design for This Report
Table 169. Key Data Information from Secondary Sources
Table 170. Key Data Information from Primary Sources
List of Figures
Figure 1. Hepatic Encephalopathy Drugs Product Picture
Figure 2. Global Hepatic Encephalopathy Drugs Sales Market Share by Type in 2021 & 2027
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Hepatic Encephalopathy Drugs Sales Market Share by Application in 2021 & 2027
Figure 6. Hospital Pharmacies Examples
Figure 7. Retail Pharmacies Examples
Figure 8. Online Pharmacies Examples
Figure 9. Global Hepatic Encephalopathy Drugs Sales, (US$ Million), 2016 VS 2021 VS 2027
Figure 10. Global Hepatic Encephalopathy Drugs Sales Growth Rate (2016-2027) & (US$ Million)
Figure 11. Global Hepatic Encephalopathy Drugs Sales (MT) Growth Rate (2016-2027)
Figure 12. Global Hepatic Encephalopathy Drugs Price Trends Growth Rate (2016-2027) (USD/Kg)
Figure 13. Global Hepatic Encephalopathy Drugs Revenue Market Share by Region: 2016 VS 2021
Figure 14. Global Hepatic Encephalopathy Drugs Revenue Market Share by Region: 2021 VS 2027
Figure 15. North America Hepatic Encephalopathy Drugs Revenue (Million USD) Growth Rate (2016-2027)
Figure 16. North America Hepatic Encephalopathy Drugs Sales (MT) Growth Rate (2016-2027)
Figure 17. Europe Hepatic Encephalopathy Drugs Revenue (Million USD) Growth Rate (2016-2027)
Figure 18. Europe Hepatic Encephalopathy Drugs Sales (Million USD) Growth Rate (2016-2027)
Figure 19. China Hepatic Encephalopathy Drugs Revenue (Million USD) Growth Rate (2016-2027)
Figure 20. China Hepatic Encephalopathy Drugs Sales (Million USD) and Growth Rate (2016-2027)
Figure 21. Japan Hepatic Encephalopathy Drugs Revenue (Million USD) Growth Rate (2016-2027)
Figure 22. Japan Hepatic Encephalopathy Drugs Sales (Million USD) Growth Rate (2016-2027)
Figure 23. Southeast Asia Hepatic Encephalopathy Drugs Revenue (Million USD) Growth Rate (2016-2027)
Figure 24. Southeast Asia Hepatic Encephalopathy Drugs Sales (Million USD) Growth Rate (2016-2027)
Figure 25. India Hepatic Encephalopathy Drugs Revenue (Million USD) Growth Rate (2016-2027)
Figure 26. India Hepatic Encephalopathy Drugs Sales (Million USD) Growth Rate (2016-2027)
Figure 27. Global 5 Largest Hepatic Encephalopathy Drugs Players Market Share by Revenue in Hepatic Encephalopathy Drugs: 2016 & 2020
Figure 28. Hepatic Encephalopathy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020
Figure 29. Global Hepatic Encephalopathy Drugs Revenue Share by Type (2016-2021)
Figure 30. Global Hepatic Encephalopathy Drugs Revenue Growth Rate by Type in 2016 & 2020
Figure 31. Global Hepatic Encephalopathy Drugs Revenue Share by Application (2016-2021)
Figure 32. Global Hepatic Encephalopathy Drugs Revenue Growth Rate by Application in 2016 & 2020
Figure 33. North America Hepatic Encephalopathy Drugs Sales Market Share by Type in 2020
Figure 34. North America Hepatic Encephalopathy Drugs Sales Market Share by Application in 2020
Figure 35. Europe Hepatic Encephalopathy Drugs Sales Market Share by Type in 2020
Figure 36. Europe Hepatic Encephalopathy Drugs Sales Market Share by Application in 2020
Figure 37. China Hepatic Encephalopathy Drugs Sales Market Share by Type in 2020
Figure 38. China Hepatic Encephalopathy Drugs Sales Market Share by Application in 2020
Figure 39. Japan Hepatic Encephalopathy Drugs Sales Market Share by Type in 2020
Figure 40. Japan Hepatic Encephalopathy Drugs Sales Market Share by Application in 2020
Figure 41. Southeast Asia Hepatic Encephalopathy Drugs Sales Market Share by Type in 2020
Figure 42. Southeast Asia Hepatic Encephalopathy Drugs Sales Market Share by Application in 2020
Figure 43. India Hepatic Encephalopathy Drugs Sales Market Share by Type in 2020
Figure 44. India Hepatic Encephalopathy Drugs Sales Market Share by Application in 2020
Figure 45. Key Raw Materials Price Trend
Figure 46. Manufacturing Cost Structure of Hepatic Encephalopathy Drugs
Figure 47. Manufacturing Process Analysis of Hepatic Encephalopathy Drugs
Figure 48. Hepatic Encephalopathy Drugs Industrial Chain Analysis
Figure 49. Channels of Distribution
Figure 50. Distributors Profiles
Figure 51. Bottom-up and Top-down Approaches for This Report
Figure 52. Data Triangulation
Figure 53. Key Executives Interviewed